We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+11.18%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$900M
AUM Growth
-$66.1M
Cap. Flow
-$123M
Cap. Flow %
-13.72%
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
27
Reduced
28
Closed
14

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.5M
2
UTHR icon
United Therapeutics
UTHR
+$23.6M
3
HUM icon
Humana
HUM
+$19.6M
4
SKIN icon
SkinHealth Systems
SKIN
+$14.5M
5
MCRB icon
Seres Therapeutics
MCRB
+$11.1M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$51.8M
2
EXAS
Exact Sciences
EXAS
+$30.2M
3
SNN icon
Smith & Nephew
SNN
+$14.9M
4
SIBN icon
SI-BONE Inc
SIBN
+$10.6M
5
ACLX
Arcellx
ACLX
+$9.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Consumer Staples 2.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
101
Sutro Biopharma
STRO
$416M
$120K 0.01%
+2,589
New +$129K
ENTA icon
102
Enanta Pharmaceuticals
ENTA
$377M
– –
-116,514
Closed -$4.71M
KYNB
103
Kyntra Bio
KYNB
$27.4M
– –
-5,179
Closed -$2.42M
LNTH icon
104
Lantheus
LNTH
$6.59B
– –
-113,700
Closed -$9.39M
MDXH icon
105
MDxHealth
MDXH
$23.4M
– –
-60,000
Closed -$194K
OBIO icon
106
Orchestra BioMed
OBIO
$247M
– –
-60,450
Closed -$1.18M
RXST icon
107
RxSight
RXST
$260M
– –
-80,000
Closed -$1.33M
TNDM icon
108
Tandem Diabetes Care
TNDM
$1.38B
– –
-203,300
Closed -$8.26M
XBI icon
109
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.92B
– –
-2,080,000
Closed -$159M
PVLA
110
Palvella Therapeutics
PVLA
$2.02B
– –
-51,686
Closed -$4.04M
NARI
111
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-101,450
Closed -$6.26M
ABCM
112
DELISTED
Abcam PLC
ABCM
– –
-279,971
Closed -$3.77M
PRDS
113
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
– –
-1,250,000
Closed -$1.65M
ISEE
114
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,127,043
Closed -$51.8M
CSII
115
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-95,346
Closed -$1.89M
1 2 3 4
5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Soleus Capital Management held 115 positions worth $900M, down 6.9% from $966M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management withdrew a net $123M in Q2 2023, closing 14 positions and reducing 28 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Teva Pharmaceuticals worth $32M.

  • Soleus Capital Management's largest Q2 2023 buy was Teva Pharmaceuticals: 4,250,000 shares worth $32M.
  • Soleus Capital Management added most to United Therapeutics in Q2 2023, an estimated $23.6M increase.
  • Soleus Capital Management's biggest Q2 2023 reduction was Exact Sciences, cutting an estimated $30.2M.
  • Soleus Capital Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $51.8M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $900M portfolio in Q2 2023.
  • Soleus Capital Management opened 38 new positions and closed 14 in Q2 2023.
  • Soleus Capital Management's portfolio value fell 6.9% quarter-over-quarter to $900M.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.